Rxi Pharma: Phase 2 Trial With RXI-109 Meets Primary Effectiveness Objective

RXi Pharmaceuticals Corp. (RXII) a clinical-stage company developing a new class of RNAi-based therapeutics, announced positive results with its lead clinical compound RXI-109 for dermal scarring in a Phase 2 clinical trial.

from RTT - Biotech http://ift.tt/2CAhYRA
via IFTTT